BR112023018473A2 - Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios - Google Patents
Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatóriosInfo
- Publication number
- BR112023018473A2 BR112023018473A2 BR112023018473A BR112023018473A BR112023018473A2 BR 112023018473 A2 BR112023018473 A2 BR 112023018473A2 BR 112023018473 A BR112023018473 A BR 112023018473A BR 112023018473 A BR112023018473 A BR 112023018473A BR 112023018473 A2 BR112023018473 A2 BR 112023018473A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- pain
- catalytically inactive
- inflammatory disorders
- chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2021/050783 WO2022208039A1 (en) | 2021-03-30 | 2021-03-30 | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023018473A2 true BR112023018473A2 (pt) | 2023-11-14 |
Family
ID=75396825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023018473A BR112023018473A2 (pt) | 2021-03-30 | 2021-03-30 | Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250066755A1 (https=) |
| EP (1) | EP4297773A1 (https=) |
| JP (2) | JP7659653B2 (https=) |
| KR (2) | KR20230155007A (https=) |
| CN (2) | CN117396217A (https=) |
| AU (2) | AU2021438810B2 (https=) |
| BR (1) | BR112023018473A2 (https=) |
| CA (1) | CA3211472A1 (https=) |
| TW (1) | TW202304502A (https=) |
| WO (1) | WO2022208039A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023089343A1 (en) * | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
| GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| DK1084146T3 (da) | 1998-05-13 | 2003-02-03 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf |
| ES2205849T3 (es) | 1998-07-22 | 2004-05-01 | Osprey Pharmaceuticals Limited | Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares. |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| HK1046020B (en) | 1999-08-25 | 2007-05-11 | Allergan, Inc. | Activatable recombinant neurotoxins |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| PL1830872T3 (pl) | 2004-12-01 | 2011-09-30 | Sec Dep For Health | Białka fuzyjne |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| ES2369558T3 (es) | 2005-09-19 | 2011-12-01 | Allergan, Inc. | Toxinas clostridiales y toxinas clostridiales activables. |
| AU2007272515B2 (en) | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| JP2009543558A (ja) | 2006-07-11 | 2009-12-10 | アラーガン、インコーポレイテッド | 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素 |
| SG10201606666XA (en) | 2012-05-30 | 2016-09-29 | Harvard College | Engineered Botulinum Neurotoxin |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| CN107108703B (zh) | 2015-01-09 | 2022-09-23 | 益普生生物创新有限公司 | 阳离子神经毒素 |
| PT3274364T (pt) | 2015-03-26 | 2021-11-05 | Harvard College | Neurotoxina botulínica manipulada |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3481852B1 (en) * | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| UA128185C2 (uk) | 2018-01-29 | 2024-05-01 | Іпсен Біофарм Лімітед | Ботулінічний нейротоксин, який розщеплює ненейронний snare |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| WO2020219358A2 (en) * | 2019-04-17 | 2020-10-29 | Children's Medical Center Corporation | Catalytically inactive botulinum neurotoxin-like toxins and uses thereof |
| GB201914034D0 (en) * | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
-
2021
- 2021-03-30 JP JP2023559998A patent/JP7659653B2/ja active Active
- 2021-03-30 EP EP21716841.8A patent/EP4297773A1/en active Pending
- 2021-03-30 KR KR1020237035244A patent/KR20230155007A/ko not_active Ceased
- 2021-03-30 US US18/552,457 patent/US20250066755A1/en active Pending
- 2021-03-30 BR BR112023018473A patent/BR112023018473A2/pt unknown
- 2021-03-30 WO PCT/GB2021/050783 patent/WO2022208039A1/en not_active Ceased
- 2021-03-30 CA CA3211472A patent/CA3211472A1/en active Pending
- 2021-03-30 AU AU2021438810A patent/AU2021438810B2/en active Active
- 2021-03-30 CN CN202180098695.XA patent/CN117396217A/zh active Pending
- 2021-03-30 KR KR1020257013523A patent/KR20250060320A/ko active Pending
-
2022
- 2022-03-30 CN CN202280038084.0A patent/CN117396218A/zh active Pending
- 2022-03-30 TW TW111112192A patent/TW202304502A/zh unknown
-
2024
- 2024-10-07 AU AU2024227147A patent/AU2024227147A1/en active Pending
- 2024-12-25 JP JP2024228411A patent/JP2025060836A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117396217A (zh) | 2024-01-12 |
| JP7659653B2 (ja) | 2025-04-09 |
| CA3211472A1 (en) | 2022-10-06 |
| CN117396218A (zh) | 2024-01-12 |
| AU2021438810A9 (en) | 2024-01-04 |
| AU2024227147A1 (en) | 2024-10-31 |
| KR20250060320A (ko) | 2025-05-07 |
| US20250066755A1 (en) | 2025-02-27 |
| AU2021438810B2 (en) | 2024-07-18 |
| AU2021438810A1 (en) | 2023-09-21 |
| EP4297773A1 (en) | 2024-01-03 |
| JP2024509634A (ja) | 2024-03-04 |
| WO2022208039A1 (en) | 2022-10-06 |
| TW202304502A (zh) | 2023-02-01 |
| KR20230155007A (ko) | 2023-11-09 |
| JP2025060836A (ja) | 2025-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023020057A2 (pt) | Tratamento de dor e distúrbios inflamatórios | |
| BR112022017930A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
| BR112022014623A2 (pt) | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos | |
| BRPI0509207A (pt) | moduladores canabinóides de tetraidro-indazol | |
| BR112022012969A2 (pt) | Moléculas de ligação, molécula de ácido nucleico isolada, vetor, célula hospedeira, composição farmacêutica, usos da molécula de ligação, métodos para produzir a molécula de ligação, tratar um indivíduo com câncer e suprarregular ou prolongar a atividade de células t citotóxicas em um indivíduo com câncer | |
| BR112019005895A2 (pt) | moléculas de ligação que modulam uma atividade biológica expressa por uma célula | |
| ATE533853T1 (de) | Botulinumtoxin-screening-assays | |
| BR112021016272A2 (pt) | Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos | |
| BR112023018473A2 (pt) | Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios | |
| CR20220618A (es) | Nuevas proteinas de unión a repeticiones de anquirina y sus usos | |
| BRPI0417493B8 (pt) | uso de uma toxina botulínica para tratamento de distúrbios da pele | |
| BR112022027028A2 (pt) | Composições para aumentar a meia-vida de um agente terapêutico em felinos e métodos de uso | |
| BR112023025528A2 (pt) | Peptídeos grampeados e métodos destes | |
| BR112022013780A2 (pt) | Moléculas de anticorpo para c5ar1 e usos das mesmas | |
| Li et al. | A multi‐center comparative efficacy and safety study of two different hyaluronic acid fillers for treatment of nasolabial folds in a Chinese population | |
| BR112014019504A2 (pt) | alérgenos da erva-dos-prados e métodos e usos para modulação de resposta imune | |
| TOKUNAGA et al. | Development of a Japanese version of the Self-Concept Clarity (SCC) Scale. | |
| BR112022024279A2 (pt) | Contator de passagem paralela tendo camadas ativas | |
| BR112023020622A2 (pt) | Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo | |
| CL2024002462A1 (es) | Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2 | |
| NO20075695L (no) | Fremgangsmate til a behandle eller forhindre type-2 diabetes | |
| BR112021020322A2 (pt) | Sistemas, métodos e composições para tradução e transcrição in vitro recombinante que utilizam proteínas termófílicas | |
| BR112023023400A2 (pt) | Anticorpo agonista anti-pd-1 humano e composição farmacêutica compreendendo o anticorpo para tratamento ou prevenção de doenças inflamatórias | |
| MX2022016591A (es) | Moléculas de anticuerpo contra april y usos de las mismas. | |
| BRPI0414174A (pt) | moléculas de ligação nogo-a e o uso farmacêutico das mesmas |